The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ELIGARD (Mundipharma Pty Ltd)
Product name
ELIGARD
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
Leuprorelin acetate
Registration type
EOI
Indication
ELIGARD 45mg 6 month is now also indicated for the treatment of children 2 years of age and older with central precocious puberty (CPP).